Objective: We explore here a novel model for amyloidogenesis in Alzheimer's disease (AD). This new perspective on AD amyloidosis seeks to provide a rational framework for incorporating recent and seemingly independent findings on the antimicrobial role of b-amyloid and emerging experimental, genetic, and epidemiological data, suggesting innate immune-mediated inflammation propagates AD neurodegeneration. 
Beginning of the molecular genetic era of AD research
Alzheimer disease (AD) is the most common type of dementia diagnosed in the elderly population. Pathologically, AD is characterized by cerebral deposition of the amyloid b-protein (Ab) as b-amyloid senile plaques, together with the intracellular aggregation of microtubule-associated tau proteins as neurofibrillary tangles (NFTs), and neuroinflammation. Thirty-four years ago the molecular genetic era of AD research began in earnest with the discovery of the Ab protein, which enabled the cloning of the amyloid-b precursor protein gene (APP). Findings from genetic studies continue to guide AD research efforts (reviewed in Bertram and Tanzi, 2010 [1] ). The cloning of APP was reported concurrently with linkage of early onset familial Alzheimer's disease (EO-FAD) to genetic markers on chromosome 21. Interestingly, the four EO-FAD families originally linked to chromosome 21 turned out to actually be linked to the presenilin 1 (PSEN1) gene on chromosome 14. Despite this type I error, the genetic markers and linkage map used in the original chromosome 21 EO-FAD linkage study later enabled identification of other EO-FAD families that were used to find the first EO-FAD mutation in APP. This particular mutation was identified after the discovery of the first pathogenic APP mutation in a Dutch family with hereditary cerebral hemorrhage with amyloidosis.
Since the cloning of APP and early genetic linkage studies of EO-FAD, a diverse array of mutations have been found, virtually all of which lead to increased generation of longer and more amyloidogenic forms of Ab [1] . EO-FAD mutations in the APP, PSEN1, and PSEN2 genes now number over 300 [2] , and the vast majority increase the ratio of the 42 amino acid isoform (Ab42) to the 40 residue (Ab40) species, leading to enhanced cerebral amyloidosis and EO-FAD. b-Amyloid was shown in mice to cause neuroinflammation and cognitive impairment, but not NFTs, leading to a debate as to whether b-amyloid causes AD.
However, more recently, a 3D human stem cell-derived neural cell culture system expressing EO-FAD mutations in APP and PSEN1 has shown that b-amyloid directly induces the formation of NFTs from endogenous tau proteins [3] . These data strongly support the amyloid hypothesis of AD and suggest direct induction of tauopathy by Ab, not necessarily requiring a long cascade of multicellular events. Interestingly, in rare cases, autopsies reveal elderly individuals with widespread Ab deposition and tangles, but with no signs of dementia at the time of death. These have been termed "resilient" brains and are usually characterized by the absence of gliosis and neuroinflammation [4] . These findings emphasize the role of aberrant innate immunity as the third major pathological hallmark of AD.
Although Ab deposition has been shown to trigger both tangle pathology and inflammation, the mechanism by which age-related Ab deposition occurs in the brain has remained unclear. We (R.D.M. and R.E.T.) have previously shown that Ab functions as an antimicrobial peptide (AMP) [5] and that Ab deposition can be rapidly induced in mice, Caenorhabditis elegans (C. elegans), and neural cell-based models of AD as an innate immune defense mechanism against microbial pathogens [6] . Based on these findings, we have put forward the Antimicrobial Protection Hypothesis of AD. This new etiology model characterizes Ab deposition as an innate immune response that normally protects against microbial infection in brain.
Ab is a normal constitutive catabolic product
Ab is generated by extracellular and intramembrane endoproteolytic cleavage of APP [7] . APP cleavage is mediated by multiple proteases, including initial cleavage by a-secretase (disintegrin and metalloproteinase domaincontaining protein 10 or ADAM10) or b-secretase (betasite APP-cleaving enzyme or BACE1), followed by cleavage by the g-secretase complex, which uses the presenilins (PSEN1 and PSEN2) and other proteins including nicastrin, presenilin enhancer 2 (PEN2), and pharynx-defective-1a (APH1a). Alternative cleavages/processing at the b and/or g sites generate different Ab isoforms, but Ab40 and Ab42 isoforms are the major products. Fully penetrant autosomal dominant mutations in APP, PSEN1, or PSEN2 that alter Ab generation lead to EO-FAD.
The Ab peptide has traditionally been characterized as a functionless byproduct of APP catabolism. This surmise has its origins in the early days of Ab research. When Ab was first identified, intramembrane cleavage was considered to be an abnormal proteolytic pathway. It was assumed that Ab generation resulted from an exclusively diseaseassociated proteolytic activity and, thus, that the peptide lacked a normal physiological function. However, in the late 1990s, proteases with intramembrane-cleaving activity began to be identified [8] , including g-secretase that generates Ab. Intramembrane cleavage is now understood to be a normal proteolytic pathway that mediates the generation of diverse functional biomolecules. Furthermore, Ab has been conclusively demonstrated to be a normal constitutively generated human and animal neuropeptide. Nonetheless, the view that Ab is functionless remains widely held, despite evidence highlighting that the human Ab sequence is 100% conserved across most vertebrate species up to at least 400 million years (humans share Ab42 sequences with coelacanths, an ancient fish taxon) [9] . The absence of an identified physiological role for Ab has led to a widespread view that the peptide's activities are unfortunate accidents of protein physiochemistry. This, in turn, has helped foster therapeutic strategies aimed at ameliorating AD by eliminating Ab. However, given the emerging findings on the role Ab plays in innate immunity [5, 6] , there is a clear and urgent need to more carefully assess the dominant model of AD pathogenesis emerging from errant Ab activities that has guided therapeutic strategies for over three decades.
Innate immunity and neuroinflammation play central roles in AD
Neuroinflammation has long been recognized as a major component of AD pathology. In prevailing AD models, neuroinflammation in brain is initiated and driven by the progression of AD pathology, principally Ab deposition and neuronal cell death. However, Ab deposition is also driven by neuroinflammation, in other words, the relationship between the innate immune system and AD pathology is bidirectional. In experimental models, disruption of immune pathways attenuates Ab deposition [10] . Microglial cell activation also plays a role in AD-related neuroinflammation, with key regulatory contributions from the AD genes, Siglec-3 (CD-33) and triggering receptor expressed on myeloid cells 2 (TREM2) [11, 12] . Moreover, human innate immune genes have emerged as the largest group of risk factors for late-onset AD [12] . Findings from resilient brains suggest neuroinflammation may be responsible for the widespread neuronal death that characterizes late-stage AD.
Ab shows antimicrobial activity
Recent evidence strongly suggests that Ab plays a role as an AMP in the innate immune system. Comparison of Ab and human cathelicidin antimicrobial peptide (LL-37), an archetypal human AMP, reveals extensive and striking parallels between the two peptides (Supplementary Table 1) . Moreover, synthetic Ab can reduce the growth of common pathogens by up to 200-fold in vitro [5] . Ab displays activity against both gram-positive and gram-negative bacteria and also against the fungus Candida albicans [5] . AD brain homogenates from Ab-enriched regions also show elevated antimicrobial activity compared with non-AD control samples. Parallel findings have now been independently reported for Ab in antiviral assays. White et al. report that Ab peptide strongly inhibits the infectivity of influenza A virus in cell culture [13] while Bourgade et al. [14, 15] report similar findings for herpes simplex virus type 1 (HSV1).
Data from animal models and human clinical trials are also suggestive of a protective role of Ab. Genetically modified mice with impaired Ab generation are reported to show dramatic dose-dependent increases in postpartum mortality unless reared under sterile conditions [16] . Adaptive immune functions appear normal in the modified mice. Pharmacologic lowering of Ab is also reported to be associated with increased risk of infection in humans [17] .
Most recently, we (R.D.M. and R.E.T.) have shown that expression of human Ab protects and increases host survival, in transformed cell culture and transgenic C. elegans and mouse infection models [6] . Conversely, mortality is increased among encephalitic APP knockout mice with low murine Ab expression. With regard to mechanism, the heparin-binding activity of soluble Ab oligomers appears to mediate targeting of microbial cell wall carbohydrates. Bound oligomers then provide a nidus and anchor for Ab fibril propagation (Fig. 1) . Growing Ab fibrils capture, agglutinate, and finally entrap microbes in a proteaseresistant network of b-amyloid. The antimicrobial pathway identified for Ab parallels the protective microbial agglutination and entrapment activities of classical AMPs, including LL-37 and a-defensin six peptides [18, 19] . However, the potential for AMP activities to display protective/damaging duality is well recognized, and AMPs are implicated in several major late-life disorders [20] , including amyloidopathies [21] . The emergence of a protective antimicrobial role for Ab is consistent with the growing evidence implicating innate immunity in AD pathology. Moreover, the finding that Ab may have a normal protective role is highly provocative, suggesting that this hallmark AD pathology may be the early stage of an immune response that ultimately leads to neurodegeneration.
AMPs mediate innate immunity
AMPs are the primary effector proteins of the innate immune system. AMPs target bacteria, mycobacteria, enveloped viruses, fungi, protozoans, and, in some cases, transformed or cancerous host cells [22] . AMPs are also potent immunomodulators. The best-studied AMPs in humans are the six a-defensins, a series of b-defensins, and the cathelicidin peptide LL-37, but a wide variety of evolutionary ancient AMP-like sequences persist in the human genome (searches of the Antimicrobial Peptide Database at http://aps.unmc.edu/AP/main.php and Linking Antimicrobial Peptide database at http://biotechlab.fudan. edu.cn/database/lamp/ returned a total of 105 human antimicrobial peptides). All known AMPs are generated from the proteolytic cleavage of larger precursor proteins [22] . We stress that human AMPs are not incidental vestiges of immune evolution. Low AMP levels can result in seriously compromised immunity. Deficiency in LL-37, for example, causes morbus Kostmann syndrome, an immunodeficiency disorder that, left untreated, typically leads to death from infection in the first year of life [23] .
AMPs are ubiquitously expressed, although the expression of individual species can be systemic or tissuespecific [22] . AMPs are expressed at high levels in brain and other immunoprivileged organs where the activities of adaptive immunity are constrained. Consistent with a role as an AMP, the highest Ab concentrations are found in the leptomeninges [24, 25] , the first line of defense against cerebral infection and a tissue enriched in immuneassociated proteins. AMPs can be either constitutive or inducible. Inducible AMPs are upregulated in response to immune challenge. Available data suggest Ab is an inducible, rather than constitutive, AMP. Exposure to viral or bacterial pathogens upregulates Ab expression in nontransformed cell culture models and wild-type rat brain [26, 27] . Thus, the central nervous system (CNS) antimicrobial response likely include pathways that upregulate Ab. Chronic infection and other conditions that lead to longterm immune-mediated upregulation of Ab may increase amyloid deposition.
Innate and adaptive immunity normally function as a continuum and AMPs play important roles in both immune systems. Indeed, AMPs are sometimes called the alarmins because of their role in activating adaptive immune pathways, including the complement system. Consistent with the antimicrobial protection model for AD pathology, Ab oligomers have been reported to bind and activate the complement cytolytic pathway. In prevailing AD models, Ab-mediated activation of complement is an abnormal and intrinsically pathological activity. However, in the antimicrobial protection model, activation of compliment is a normal part of Ab activities as an AMP of innate immunity. It seems likely compliment, and possibly other adaptive immune pathways, are activated by Ab in AD. What remains to be determined is if Abmediated activation of immune pathways in AD is pathological dysregulation or an immune response to genuine chronic infection.
Oligomerization and entrapment are integral for AMP action
AMP pathways mediating rapid microbial death typically involve cell membrane disruption [28] . However, micromolar peptide concentrations are often required for AMPmediated microbial membrane disruption. At sublytic AMP concentrations, inhibition of microbial attachment, agglutination, and entrapment activities are emerging as key mediators of host protection [29] [30] [31] . Oligomerization and fibrilization are normal activities for AMPs, mediating both lytic and nonlytic activities [19, 30, 32] . Dimers, middle-order oligomers (,100 kDa), larger multimers, and fibrils are generated in bulk solution or in association with lipid bilayers [31, 33] . AMP fibrillization also plays a key role in microbial agglutination [19, 30] . As with Ab, AMPs exhibit cooperativity during oligomer assembly.
Oligomerization is integral to AMP function, and soluble AMP oligomers have been confirmed to have potentiated bioactivity compared with monomeric species, including the human defensins and LL-37 [33] . Moreover, AMP oligomers have been shown to mediate the targeting and disruption of microbial cell membranes [34, 35] and increase resistance to microbial proteases that target host AMPs [36] . In addition, AMP oligomerization typically generates multiple molecular forms that increase the molecular diversity within AMP families. Polymorphic AMP oligomers show a markedly broader activity spectra than homogenous or non-oligomeric species [37, 38] .
As with all known AMPs, Ab is generated by proteolytic cleavage of a larger precursor. Ab has physiochemical characteristics found among self-complementary peptides (sometimes called Lego peptides), with two distinct hydrophobic and hydrophilic surfaces. Self-complementary peptides show a strong propensity to self-assemble into polymorphic oligomers [39] , and AMPs typically exhibit self-complementarity. For Ab, self-association leads to the generation of higher order polydisperse and polymorphic oligomers. Ab oligomerization is highly sensitive to the peptide-starting conditions and the environment in which oligomers are generated. Within Ab assemblies, domain swapping between monomeric units stabilizes oligomeric structures [40] .
The broad role for oligomerization in normal AMP function suggests that the propensity of Ab to form oligomers may not be the intrinsically abnormal behavior portrayed in prevailing AD models. Instead, Ab oligomerization may normally mediate antimicrobial actions, as is the case with established AMPs. Consistent with a key role for oligomerization, the specific in vitro antimicrobial activity of cellderived and synthetic Ab oligomers is at least two orders of magnitude (log 10 ) higher than monomeric in vitro prepared synthetic material [5, 6] . Furthermore, we have recently shown that Ab oligomerization mediates binding, anti-adhesion, agglutination, and entrapment activities against microbial pathogens [6] . Ab-mediated microbial entrapment has recently been confirmed in independent studies [13, 41] . In addition to entrapment, there is also emerging evidence that Ab may mediate direct pathogen killing via the production of reactive oxygen species (ROS). ROS generation has been shown to play a role in the antimicrobial activities of metallopeptide AMPs that bind redox-active metals [42, 43] . The N-terminus of Ab is implicated in specific metal binding (copper and zinc) and metal-catalyzed ROS generation. The specific Ab residues involved remain to be delineated, but ROS generation is greatly potentiated by oligomerization of the peptide [44] .
AMPs are immunomodulators
Both innate and adaptive immune pathways are modulated by AMPs [45] ; for example, AMPs can act as chemokines to recruit immune cells to the site of infection. AMPs can be proinflammatory or anti-inflammatory depending on prevailing milieu conditions. In addition to chemokine activity, AMPs can act as cytokine inducers as well as regulators of host cell differentiation, autophagy, apoptosis, and pyroptosis [28, 45] . The well-characterized activities of LL-37 provide an informative model for the immunomodulatory pathways of AMPs. LL-37 induction downregulates cytotoxic tumor necrosis factor and upregulates a panel of chemokine receptors [46] . LL-37 is also a ligand for formyl peptide receptor-like 1, a receptor that mediates chemoattraction of immune cells [47] . Other activities include the promotion of wound-healing and the modulation of cell death processes. Thus, immune defense mediated by LL-37 involves multiple targets in addition to invading microbes (reviewed in Mansour et al. 2014 [45] ). As an AMP, Ab is likely to also modulate multiple immune pathways.
AMP immunomodulation is mediated by the binding of host biomolecules linked to immunity. Apolipoprotein E protein (apoE) is among the most widely studied Ab ligands because expression of the ε4 allele apoE (APOE-ε4) is a risk factor for AD. Humans express apolipoprotein E2 (apoE2), 3 (apoE3), and 4 (apoE4) isoforms. Despite intense study, it remains unclear why expression of APOE-ε4 increases AD risk. Investigations to date have focused on models in which apoE4 is a less effective chaperone than apoE3 or apoE2, leading to reduced peptide clearance and an escalation of Ab activities held to be pathogenic. However, apoE plays an important role in innate immunity [48] , modulating cytokine expression and mediating innate immune neuroinflammation in response to infection. The proinflammatory activities of APOE alleles differ with rank order APOE-ε4 . APOE-ε3 . APOE-ε2. Interestingly, the heighted inflammatory response associated with the APOE-ε4 allele promotes survival in high-burden pathogen environments [49] . Apolipoproteins are ligands for AMPs, including LL-37 [50] . Apolipoprotein/AMPs complexes have unique immunomodulatory activities, and Ab binding is likely to modulate apoE immune activities. ApoE is also targeted by pathogens, and apoE4 expression is associated with increased susceptibility to several microbes, including neurotrophic viruses [51] . Viewed from the perspective of the Antimicrobial Protection Hypothesis, possible roles for apoE4 in AD extend well beyond the poor Ab chaperone model. A fuller understanding of the role apoE plays in Ab-mediated immune pathways may well yield insights into how APOE-ε4 is an important AD risk factor. AMP-mediated immunomodulation plays an important role in combating infection. However, dysregulated AMP immunomodulation is also increasingly recognized as important for the pathogenesis of a range of inflammation diseases, including atherosclerosis, lupus, arthritis, cystic fibrosis, Crohn's disease, asthma, psoriasis, rosacea, and atopic dermatitis [52] . LL-37 activities can either promote or inhibit inflammation depending on tissue and cellular conditions [45] . Consistent with identity as an AMP, administered synthetic Ab can be proinflammatory in the CNS [53] and anti-inflammatory in the periphery [54] . However, in prevailing AD models, Ab-mediated immunomodulation is characterized as inadvertent and intrinsically pathological. The emerging AMP role for Ab may lead to a more balanced understanding of the normal immunomodulatory activities of the peptide and their possible contribution to AD pathogenesis.
Ab and AMP host cell cytotoxicity
The normal protective actions of AMPs include killing infected or cancerous host cells. However, dysregulated AMP host cytotoxicity targets healthy cells and is linked to disease. Pathological AMP cytotoxicity typically targets specific host cell types and is often driven by excessive or persistent expression. Pertinent to Ab and AD, neuronspecific cytotoxicity of the antimicrobial eosinophil cationic protein directly mediates neurodegeneration in hypereosinophilic syndrome [55] . Dysregulated AMP oligomerization plays a key role in pathological host cytotoxicity [32, 34] . Well-characterized AMPs are responsible for at least three human amyloidopathies [56] , including corneal amyloidosis from lactoferrin, senile seminal vesicle amyloid (SSVA) from semenogelin peptide, and isolated atrial amyloidosis (IAA) from the atrial natriuretic peptide, a recently identified member of the natriuretic AMP family. SSVA and IAA develop in the elderly and are among the most common human amyloidopathies [57, 58] . Dysregulation of AMP immunomodulatory activities is also thought to play a role in the pathology of a wide range of chronic inflammatory diseases and is increasingly implicated in neurodegenerative disorders [59] . Thus, precedents for AMP-mediated amyloidosis and inflammatory pathology are well established, and a pathogenic role for Ab in AD is not inconsistent with a normal protective function for the peptide as an effector protein of innate immunity.
With regard to AD, the contribution of neurotoxic Ab species to overall neuronal death remains unclear. Mounting experimental, genetic, and epidemiological data are consistent with inflammatory pathways activated in late AD as the dominant mediator of neuronal death [4, 11, 12] . However, Ab may directly mediate neurodegeneration early in the disease, and the role played by neurotoxic oligomeric species continues to be an important research focus. In prevailing models of Ab neurotoxicity, interactions with plasma or mitochondrial membranes typically mediate the peptides' neurotoxic activities, leading to a range of possible neuropathologies, including synaptic loss, cytoskeleton disruption, apoptosis induction, and mitochondrial dysfunction. We believe the antimicrobial protection model of AD can provide insights into the neurotoxic actions of Ab. We will focus our discussion on how AMP models can inform understanding of neurotoxic Ab pathways and explore possible immune roles for host cell cytotoxicity.
Ab host cell cytotoxicity is mediated by oligomeric species. However, neurotoxicity appears to require highly specific oligomer conformations and possibly post-translational modifications. Indeed, generating experimental oligomeric Ab species with consistent neurotoxic activity has proved to be a major challenge. By contrast, Ab oligomers show broad-spectrum antimicrobial activities, and microbial cell cytotoxicity per se does not appear to be associated with specific Ab oligomer conformations. Thus, the vast majority of Ab oligomers show protective cytotoxic actions against microbes but are not harmful to host cells. As previously discussed, in in vitro experiments, Ab oligomers show enhanced antimicrobial potency and activity spectra compared with homodisperse monomeric peptides [60] . Generation of a pool of polymorphic polydisperse oligomers likely serves to increase and broaden the protective activities of Ab in brain. In contrast to prevailing views of Ab oligomerization, in the innate immune model, the generation of diverse soluble oligomer species is key for Ab 0 s immune AMP role and is not an intrinsically neurotoxic pathway.
Oligomer conformation is key for cytotoxic Ab activities targeting neurons. However, in vivo peptide modifications also modulate Ab activities and maybe linked to neurotoxicity. Reported in vivo, post-translational modification of Ab includes oxidation, phosphorylation, nitration, racemization, isomerization, pyroglutamylation, glycosylation, truncation, and intermolecular interactions [61] . In prevailing AD models, Ab is not viewed as a normal substrate for posttranslational modification, and modified species are typically characterized as nonphysiological. Studies have focused on the potential pathological roles these species may play, including neurotoxic activities [61] . However, for classical AMPs, post-translational modifications appear to be crucial for both functionality and oligomerization.
For example, citrullination (arginine to citrulline conversion) of LL-37 and other AMPs alters immunomodulatory activities and is essential for extracellular trap (ET) generation and pathogen killing [62] . The most potent antimicrobial Ab species identified experimentally are cell-derived [60] , consistent with a role for post-translational modification in the peptides in vivo AMP activities. Given findings for classical AMPs, post-translational modifications appear likely to regulate the immune actions of soluble Ab oligomers, including antimicrobial and immunomodulatory activ- The leading model for how Ab may directly kill neurons involves disruption of plasma membranes through the formation of pores or carpet-like structures [63] . This widespread AMP pathway normally mediates killing of microbial cells [63] . It remains unclear why neurotoxic Ab oligomers may target neuronal membranes. AMPs discriminate prokaryotic from eukaryotic host membranes by charge and exhibit a strong specificity for anionic microbial versus zwitterionic host lipid bilayers [32, 64, 65] . Consistent with an AMP role, Ab normally shows a strong preference for anionic membranes, with soluble oligomers binding more avidly than monomeric peptide [66] . However, Ab is among the 12% to 15% of AMPs that are anionic rather than cationic peptides. AMP-entrapped bacteria secrete proteases that specifically target cationic peptides [67] . Thus, anionic AMPs evade microbial countermeasures aimed at freeing bacteria from AMP-mediated entrapment. However, one disadvantage is that anionic AMPs have reduced avidity for negatively charged microbial membranes. Binding and targeting of microbial membranes by anionic AMPs are typically mediated by positively charged regions that are enriched in cationic residues [67] . Anionic AMPs are also often metaloproteins that bind divalent zinc or copper ions. AMP-bound metal ions form cationic salt bridges with anionic membranes, increasing binding and specificity for microbial cells [67] . Ab is an anionic entrapment AMP and metalloprotein that simultaneously binds Zn 11 and Cu 11 [68] . Ab-metal binding seems likely to play a role in helping Ab oligomers to discriminate microbes from host cells. Ab oligomerization pathways generate polymorphic oligomeric species with widely differing Zn 11 and Cu 11 binding activities [68] . For neurotoxic oligomers, metal-mediated targeting of microbial membranes may be limited by how Zn 11 and Cu 11 are bound, leading to Ab species with increased propensity for binding host cells.
Neuronal membranes are also enriched in negatively charged gangliosides and phospholipid phosphatidylserine [69] , which may also contribute to targeting by Ab. Further experimentation will be necessary to validate this model of metal-mediated microbial targeting and its possible involvement in Ab's neurotoxic activities. However, our interpretation of data on metal and membrane binding serves to illustrate how an antimicrobial response model for AD pathogenesis offers a framework for rational incorporation of what appear to be disparate Ab activities.
The neurotoxic activities of Ab may also include permeabilization of host mitochondrial membranes. Mitochondria are endosymbiotic and retain the anionic membranes of prokaryotes. Mitochondrial membranes are readily bound by Ab, and the peptide has been reported to cause neuronal mitochondria dysfunction [70] . AMP-induced mitophagy and mitochondrial disruption are normal immune pathways that mediate killing of infected and unhealthy host cells. However, dysregulation of these pathways can lead to degenerative pathologies, including vascular disease mediation by the killing of healthy smooth muscle by LL-37 [71] . Understanding that targeting of neuronal mitochondria by Ab may include a normal immune pathway is likely to prompt new models of mitochondrial dysfunction in neurodegeneration. This would include shifting the genesis of Abmediated mitochondrial dysfunction from intrinsic abnormal activity to dysregulated innate immune pathway.
Finally, although pathologic when dysregulated, AMP host cytotoxicity normally mediates protective immune pathways. AMPs play an important role in killing infected and cancerous cells [72] . Indeed, LL-37 is currently being trialed as an anticancer drug (identifier NCT02225366 at clinicaltrials.gov). LL-37 also selectively kills pathogeninfected airway epithelial cells [73] . At sites of infection, LL-37 permeabilization of apoptotic leukocyte plasma membranes mediates the release of proinflammatory molecules. Conversely, AMP-mediated immune cell death is involved in the termination of acute inflammation [74] . AMPs also play a role in the elaboration of ETs through ETosis, a programmed cell death pathway for neutrophils and macrophages/monocytes that occur in response to immunochallenge [75] . ETs entrap microbes in a scaffolding composed of host cellular DNA, histones, and AMPs [76] . ET-entrapped microbes are inactivated by high local AMP and ROS levels generated by the dying host cell [77] . Neutrophil-derived ETs are associated with Ab deposits in AD brain [78] . Parallels have been drawn between the pathways that lead to neuritic plaques and ETosis [75] . In summary, targeted host cell death can be a deliberate strategy to defeat invaders. Given the wide range of protective pathways mediated by AMP host cytotoxicity, the neurotoxicity of Ab should not be assumed to be intrinsically and exclusively abnormal. Rather, Ab host cytotoxicity may mediate "beneficial suicide" pathways in normal brain. In AD, this activity may become dysregulated, leading to indiscriminate neuronal death. However, it should not be overlooked that Ab may be targeting infected or unhealthy neurons in AD brain. As we discuss later, mounting data link AD etiology with chronic neuroinfections, particularly life-long viral infections. Adaptive immune responses are largely absent from brain. If unchecked, neurons undergoing active viral replication could rapidly spread infection throughout the brain, with lethal consequences. In AD, the neurotoxic actions of Ab may be suppressing potentially serious infection, albeit at high long-term cost. The emergence of an AMP identify for Ab is likely to prompt new models and lines of enquiry that more fully capture the different roles the peptides' cytotoxic actions may play in AD and normal immunity.
FAD mutations and Ab
A convincing AD model requires consistency with the large body of genetic data on FAD and the role played by familial mutations in APP, PSEN1, and PSEN2. In the following section, we explore how these findings can be interpreted in the light of the emerging AMP role for Ab and the Antimicrobial Protection Hypothesis.
Mutations in all three EO-FAD genes, PSEN1, PSEN2, and APP, accelerate Ab deposition by increasing the Ab42:Ab40 ratio, which in turn increases Ab oligomerization. Thus, in terms of the antimicrobial protection hypothesis, EO-FAD mutations can be thought of as leading to the deposition of b-amyloid, even when not required as an antimicrobial agent. Genetic changes in isoform expression among classical AMPs also mediate disease pathology. For example, inherited mutations in the human b-defensin 1 promoter that shift isoform ratios are associated with atopic disorders, including asthma [79] . Moreover, the enhanced b-amyloid deposition seen in FAD brain parallel mutationinduced over-activation of innate immune pathways that lead to degenerative pathologies in inherited autoinflammatory syndromes. Data from Down syndrome patients appear to confirm increased amyloidosis with duplication of chromosome 21 and of the APP gene. However, not all findings are consistent with this straightforward APP dose-dependent model of amyloidosis. AD-linked 23829 C-T polymorphism has been reported to reduce DNA/protein interaction and reporter expression [80] , while four of six AD-linked promoter mutations appear to impair transcription factor binding [81] . A rare protective C allele of rs466448, unexpectedly, is associated with higher APP expression [81] . Finally, the AD-linked A454G allele increases the effect of miR-20a, arguing that APP expression is reduced. These data are inconsistent with a simple dose-dependent model for APP levels and AD pathology. Data suggest that the relationship between APP levels and AD risk is complex and prompts the speculation that additional factors are involved. A clearer elucidation of the relationship between APP expression and amyloidosis will likely prove useful for development of AD therapeutic strategies and this line of research appears to warrant further exploration.
The finding that altered Ab40/Ab42 ratios are associated with FAD has prompted a large research focus on APP processing pathways. In prevailing AD models, shifts in Ab isoform ratios are considered abnormal perturbations in homeostasis which lead to disease. However, among classical AMPs, shifts in isoform ratios are considered to be part of optimizing protective activities to meet emerging pathogen challenges, albeit sometimes with negative effects for host tissues. AMP isoforms have differing actions, and longer forms often have higher cytotoxicity, whereas shorter species exhibit more immunomodulatory activities [82] . Consistent with this trend, Ab42 appears to be more active than Ab40 against influenza and herpes viruses, bacteria, and C. albicans [5] . AMP isoforms are also known to have synergistic antimicrobial activity when expressed together, including the full-length and truncated RK-31 and KS-30 forms of LL-37 [83] . Consistent with synergistic AMP activities for Ab isoforms, recent data suggest that concomitant secretion of Ab40 and Ab42 increases protection in culture compared with host cells generating a single isoform [6] . Thus, shifts in Ab isoform expression may not be exclusively abnormal, and changes in APP processing in normal brain may reflect dynamic fine-tuning by the innate immune system during perceived immune challenge. Sustained shifts in Ab isoform expression, however, may result in AD pathology.
An emerging normal role for Ab in innate immunity would suggest that intrinsically abnormal mutation-driven changes in APP processing maybe associated with increases or decreases in infection risk. However, there is a paucity of data on infection resistance among subjects with genetically altered Ab expression. Immunocompetence has not been studied in FAD or in individuals carrying the A673T mutation in APP that lowers Ab expression [84] . Down syndrome patients overexpress Ab, but Down syndrome-associated abnormalities in adaptive immunity obfuscate identification of Ab-specific protective activities. Notably, in clinical trials, elevated infection rates in patients taking the Ablowering drug tarenflurbil are a reported side effect [17] . In addition, there are several confounding factors when considering Ab-mediated infection resistance. Increased Ab expression in humans may initially increase CNS protection. However, degeneration of the blood-brain barrier with age and/or vascular Ab pathology could increase vulnerability to brain infection in late AD. Furthermore, at least two human Ab homologs are generated from the amyloid precursor-like proteins APLP1 and APLP2. Redundant activities among related AMP family members can affect immunity in unpredictable ways. Although the antimicrobial activities of Ab homologues generated from APLPs are unclear, non-amyloidogenic processing products of APP, APLP1, and APLP2 show extensive functional redundancy likely because of the gene duplication origin for this protein family. Given that current tests are unable to identify patients with preclinical AD, retrospective epidemiological studies will likely be necessary to resolve whether patients are protected from neuropathogens early in the disease or if Ablowering drugs increase the risk for neuroinfection.
Is infection an AD risk factor?
An innate immune origin for AD pathology raises the question of what role infection may play in the disease. As discussed earlier, infection appears to upregulate Ab and can directly seed b-amyloid deposition. However, in and of itself, a normal role for Ab as an AMP is not evidence that infection mediates AD pathology. Dysregulation of innate immune pathways occurs in a range of sterile inflammatory diseases, and a genuine infection may not be needed to trigger or promote Ab pathology. However, a large and growing body of data supports some form of transmissible agent in AD. Marmosets do not normally develop AD pathology, but when injected intracerebrally with brain tissue from a patient with early-onset AD, animals developed AD-like amyloid plaques 6-7 years after inoculation; non-AD brain tissue failed to transmit disease, and the induced degeneration was transmissible to further animals [85] . The existence of dementia in a spouse has been reported to be a risk factor for AD development in their partner [86] , although this could well be ascribed to other causes. Finally, HSV1, the pathogen most widely linked to AD, shows a preference for infecting the hippocampus, the brain region most severely affected by b-amyloidosis.These observations are consistent with the potential involvement of some type of transmissible agent in AD brain. However, the identity of such an agent remains unclear.
Data have been steadily mounting that levels of microbial and/or viral pathogens are elevated in AD compared with control brain. Intriguingly, inheritance APOE-ε4 is a risk factor for both late-onset AD and CNS infection [87] . APOE ε4/ε4 homozygotes are around an order of magnitude more at risk both for AD and CNS infections. Studies by independent groups have documented the presence of abnormal levels of pathogens in AD brain, including viral, bacterial, and fungal infections (reviewed in Lathe 2014 [88] ). Consistent with the emerging AMP entrapment role for Ab and b-amyloid, brain pathogens selectively colocalize with plaques and brain regions associated with AD pathology [89, 90] . Infection has also been implicated in promoting, if not initiating, AD pathology. Recent findings from a long-term study involving over 34,000 Taiwanese patients suggest that severe acute infection with HSV1 increases the long-term risk of dementia by 2.56-fold; furthermore, aggressive treatment with antiherpetic medications returned long-term patient risk of AD to baseline [91] , pointing to a causal relationship. Over the past several years, a host of genes involved with innate immunity have also achieved significance for association with AD in genomewide association studies, including CD33, TREM2, complement receptor type 1 (CR1), and paired immunoglobulin like type 2 receptor a (PILRA) [92] . CD33 and TREM2 are cellsurface receptor genes that mediate microglia activation, CR1 is involved in the complement cascade, and PILRA is an entry receptor for HSV1 [93] . However, studies have yet to resolve unambiguously whether infection is a cause or consequence of AD. AD pathology leads to degeneration of the integrity of the blood-brain barrier and could increase susceptibility to CNS infection by blood-borne agents. Thus, the infections associated with AD may arise after the onset of the disease. Moreover, no single pathogen has been found to occur in all AD patients. The lack of association between AD and any single pathogen suggests that more than one infectious species may be able to trigger the innate immune response that can lead to Ab deposition. Unlike adaptive immunity, innate immune responses often follow similar courses irrespective of the initiating challenge. If infection triggers AD, this may explain why a sole candidate pathogen has not emerged. The finding that b-amyloid is generated in response to bacterial, fungal, and viral pathogens further supports a nonspecific antimicrobial response in AD.
Although adaptive immunity is constrained in brain, the innate immune system is highly active [94] . The immunological actions of the brain are not only confined to the CNS but also modulate peripheral immunity. Conversely, peripheral immune responses can modulate innate immune activities in brain. The emerging bidirectional pathways between CNS and peripheral immunity are referred to as the neuroimmune axis [95] . Dysregulated afferent nerve neuroimmune pathways are thought to play a role in an increasing number of neurological inflammation disorders [94, 95] . For AD, limited data are available on possible roles dysbiosis or infections outside the CNS may play in the pathology of the disease. However, given the emerging role innate immunity appears to plays in AD and links between the neuroimmune axis and neuroinflammatory disease, it may be time to give more serious consideration to possible contributions of chronic peripheral infection (potentially including enteric dysbiosis) to AD pathology.
While data strongly implicate CNS infection in AD pathology, the pathways involved remain unclear. Chronic asymptomatic infection may conceivably induce or accelerate AD progression and pathology. Alternatively, a transient infection might lead to a self-perpetuating innate immune response. It is also possible that no genuine infection is involved in AD pathology, but instead, mistaken perception of infection by the innate immune system mediates the disease. What does appear to be emerging is widespread consensus among investigators that there is an urgent need to delineate the role of infection in AD etiology [96] .
Concluding remarks
Thirty years ago, the cloning of APP accompanied by the first genetic linkage data for EO-FAD ushered in the molecular genetic era of AD research. Our understanding of the role of genetics has developed as new data have emerged, but the key premise shaping how the amyloid hypothesis is interpreted has changed little, that Ab is an intrinsically abnormal byproduct that accumulates in the brain with age. However, a new perspective has begun to emerge with mounting evidence that innate immune pathways, and possibly infection, play central roles in AD pathology. The recent discovery that Ab generation is itself part of an innate immune pathway has focused the attention of the wider AD field on alternative models for the genesis of AD pathology. The emerging antimicrobial protection model gives a fresh perspective to the amyloid hypothesis and provides a framework for rational incorporation of the disparate pathways AD neurodegeneration appears to involve. Emergence of the antimicrobial response model (The Antimicrobial Protection Hypothesis of AD) also prompts an additional novel question-are NFTs also part of an innate immune response? As was the case with Ab, tau fibrillization is widely assumed to be intrinsically abnormal. However, possible protective roles for tau fibrillization and NFTs may include capturing cytoskeleton-trafficking intracellular infectious agents. Although certainly speculative, recent lessons from Ab suggest novel models that explore an innate immune role for NFTs may be worthy of consideration.
Comparisons between Ab and the archetypal human AMP LL-37 reveal a surprising and extensive list of shared physiochemical and molecular activities (Supplementary Table 1 ). Furthermore, antimicrobial activities that parallel classical AMP actions have also been reported for other human amyloidosis-associated peptides [21] , including amylin of diabetes I and II, atrial natriuretic factor of senile cardiac amyloidosis, a-synuclein of Parkinson disease, prion protein of Creutzfeldt-Jakob disease, cystatin C of cerebral myopathy, lysozyme of nonneuropathic hereditary amyloidosis, and superoxide dismutase of amyotrophic lateral sclerosis. It remains to be determined if amyloid entrapment pathways play a role in the normal antimicrobial activities of these amyloidosis-causing peptides. However, should this prove to be the case, entrapment AMPs may emerge as important mediators of pathology across a broad range of human diseases.
Hundreds of clinical trials have been conducted to test AD treatments, with Ab being the most frequent pharmacological target [97] . However, therapeutics aimed at modulating Ab levels in brain have so far shown little efficacy in treating AD. Reasons for failure include in some cases lack of efficacy, brain permeability, and the safety of the therapies tested. For other therapies, treating Ab deposition was simply carried out too late in the pathological course of AD, given that we now know that Ab deposition occurs 10-20 years before the occurrence of clinical symptoms. In fact, there is now general agreement that therapies targeting Ab must be used presymptomatically, prodromally or, at the latest, in mild, early stage disease. We would argue that in any anti-Ab therapy, consideration should be given not to completely eradicating the peptide but instead to reducing levels so as to not deprive the brain of the increasingly evident beneficial antimicrobial properties of Ab. In prevailing AD models, pathological pathways involving Ab deposition are characterized as being intrinsically abnormal-unfortunate stochastic accidents. We believe that consideration needs to be given to AD pathologies as a pattern of physiological responses mounted by innate immunity. An antimicrobial response model may help to identify therapeutic strategies for targeting events upstream of amyloidosis which can ameliorate the destructive actions not only of Ab but also of other key inflammation pathways contributing to neurodegeneration in AD.
The Antimicrobial Protection Hypothesis of AD proposes that Ab is mobilized as a defense mechanism against (genuine or mistakenly perceived) infection. Accumulation of high levels of b-amyloid leads to tangle formation and a chronic innate immune inflammatory response that includes microglial activation. Chronic activation of innate immunity together with plaque and tangle pathology mediates neurodegeneration and, eventually, dementia. The model is consistent with findings from FAD genetic studies of APP/ Ab and the role that AMP mutation/dysregulation plays in the pathology of a wide range of late-onset degenerative diseases, including amyloidopathies.
The identification of Ab as an AMP may eventually lead to a paradigm shift in how AD pathogenesis is viewed. In addition, it will likely raise new questions as well as renew interest in lines of enquiry that have received limited consideration in the past. Not least, will the most efficacious approach to AD involve more patient-targeted treatments for what is, after all, a heterogeneous disease? This may include anti-Ab therapeutics, anti-inflammatories, and, perhaps, anti-infectives for different disease stages or AD subtypes. In any case, we believe the Antimicrobial Protection Hypothesis of AD provides a rational model for understanding the pathogenesis of the amyloid cascade and the emerging roles of Ab in CNS innate immunity.
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Future directions:
The new antimicrobial protection model provides a rational framework for understanding the genesis and progression of amyloid deposition in AD. The insight that AD pathology has its origins in an innate immune response adds further support to the growing consensus that microbes are likely involved in AD etiology. Moreover, the new model highlights the importance of increasing efforts to characterize the role infection plays in the disease.
In addition, the model suggests targeting the regulatory pathways of innate immunity may be an effective therapeutic strategies for treating AD.
